Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO Immuno-Oncology Congress 2023
- Updated safety and clinical efficacy data presented at leading immuno-oncology conference
- Exploratory studies suggest roginolisib boosts antitumoral immunity, whilst simultaneously disrupting tumor survival mechanisms
- Data suggest the potential of radiomics to assess changes in lesions over time, adding value above RECIST (Response Evaluation Criteria in Solid Tumors)
Geneva, Switzerland and Amsterdam, The Netherlands, 8 December 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces clinical results for roginolisib, a first-in-class oral allosteric modulator of PI3Kδ, presented at the ESMO Immuno-Oncology Congress 2023 in Geneva.
